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Abstract 
Objective: To directly compare the efficacy and safety of a fixed-ratio combination, 
iGlarLixi, with a premix insulin analog (BIAsp 30) as treatment advancement in type 2 
diabetes suboptimally controlled on basal insulin plus oral antihyperglycemic drugs (OADs). 
Research Design and Methods: SoliMix, a 26-week, open-label, multicenter study, 
randomized adults with suboptimally controlled basal insulin-treated type 2 diabetes (HbA1c 
≥7.5 % and ≤10 %) to once-daily iGlarLixi or twice-daily BIAsp 30. Primary efficacy 
endpoints were non-inferiority in HbA1c reduction (margin 0.3 %) or superiority in 
bodyweight change for iGlarLixi versus BIAsp 30. 
Results: Both primary efficacy endpoints were met: after 26 weeks, baseline HbA1c (8.6 %) 
was reduced by 1.3 % with iGlarLixi and 1.1 % with BIAsp 30, meeting non-inferiority (least 
squares [LS] mean difference [97.5% CI]: -0.2 [-0.4, -0.1] %; p<0.001). iGlarLixi was also 
superior to BIAsp 30 for bodyweight change (LS mean difference [95% CI] -1.9 [-2.3, -1.4] 
kg) and percentage of participants achieving HbA1c <7 % without weight gain and HbA1c <7 
% without weight gain and without hypoglycemia (all p<0.001). iGlarLixi was also superior 
versus BIAsp 30 for HbA1c reduction (p<0.001). Incidence and rates of ADA Level 1 and 2 
hypoglycemia were lower with iGlarLixi versus BIAsp 30. 
Conclusions: Once-daily iGlarLixi provided better glycemic control with weight benefit and 
less hypoglycemia than twice-daily premix BIAsp 30. iGlarLixi is a more efficacious, 
simpler, and well-tolerated alternative to premix BIAsp 30 in suboptimally controlled type 2 
diabetes requiring treatment beyond basal insulin plus OAD therapy. 
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Clinical guidelines recommend a target HbA1c of <7.0 % (<53 mmol/mol) for most 
non-pregnant adults with type 2 diabetes (1; 2), while recognizing the need to individualize 
glycemic targets based on patient preference, and treatment efficacy and safety profiles (1; 2). 
Most current guidelines advocate a stepwise introduction of pharmacotherapy for people with 
type 2 diabetes not achieving their individualized glycemic targets. With this approach, 
advancing basal insulin therapy involves four options: 1) adding rapid-acting insulin 
progressively to an existing basal insulin regimen; 2) multiple daily premix insulin doses 
(basal and prandial insulin co-formulation); 3) adding a daily or weekly glucagon-like 
peptide-1 receptor agonist (GLP-1 RA) to an existing basal insulin regimen; 4) switching to a 
once-daily fixed-ratio combination (FRC) of basal insulin and GLP-1 RA (2; 3). 
Each aforementioned treatment option has been shown to improve glycemic control 
when used to advance therapy from basal insulin but are also associated with specific adverse 
effects (4-7). GLP-1 RA therapy can be associated with gastrointestinal (GI) adverse events 
(AEs) and resultant adherence issues (4). Basal plus rapid-acting insulin regimens and premix 
insulin regimens can increase the risks of hypoglycemia and weight gain, whilst requiring 
multiple daily injections and frequent glucose monitoring that increase treatment burden and 
may reduce adherence (5-7). Despite this, premix insulins are widely used globally, 
particularly in Asia, Africa, the Middle East, China and some EU countries (8-11). 
Titratable FRCs of basal insulin and a GLP-1 RA can provide a novel alternative 
therapy advancement option to premix insulin, as tested for the first time in this randomized 
controlled trial. FRCs combine the complementary mechanisms of action of two individual 
components in one formulation; basal insulin primarily reduces fasting plasma glucose (FPG) 
while the GLP-1 RA targets post-prandial glucose (PPG). Overall, GLP-1 RAs act through a 
glucose-dependent mechanism by which they stimulate insulin secretion while preventing 
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glucagon increase (12). Short-acting GLP-1 RAs, specifically target PPG with a predominant 
gastric emptying effect, while long-acting GLP-1 RAs, exert their effect predominantly 
through pancreatic functions, resulting in a lesser impact on PPG but larger overall reductions 
in FPG (12). Two once-daily titratable FRCs of basal insulin and GLP-1 RA are available 
which are approved for use in adults with type 2 diabetes. iGlarLixi is an FRC of basal 
insulin glargine 100 units/mL (iGlar) and the short-acting GLP-1 RA lixisenatide (Lixi) (13; 
14), while IDegLira is an FRC of the basal insulin degludec and the long-acting GLP-1 RA, 
liraglutide (15; 16). Both have been shown to provide improved glycemic control versus their 
individual components, along with weight-benefits compared with basal insulin and fewer 
gastrointestinal AEs compared with their GLP-1 RA component (17-22). 
Here we report the results of the first randomized, head-to-head study directly comparing 
the efficacy and safety of an FRC (iGlarLixi) with a premix insulin (biphasic insulin aspart 
30, BIAsp 30) in adults with type 2 diabetes advancing from basal insulin plus one or two 
oral antihyperglycemic drugs (OADs).  
Research Design and Methods 
Detailed methods have been previously published (23). In brief, SoliMix was an open-
label, multicenter, randomized, 26-week study undertaken to compare the efficacy and safety 
of iGlarLixi with BIAsp 30, in adults with suboptimally controlled type 2 diabetes (HbA1c 
≥7.5 % [≥58.5 mmol/mol] and ≤10 % [≤85.8 mmol/mol]) despite receiving stable doses of 
basal insulin plus OADs (metformin ± sodium-glucose cotransporter-2 [SGLT2] inhibitor) 
for 3 months. Exclusion criteria included individuals with type 1 diabetes, BMI of <20 and 
≥40 kg/m2, basal insulin dose of <20 U or >50 U at screening, and use of any 
antihyperglycemic agent other than basal insulin, metformin, or SGLT2 inhibitors in the 3 
months prior to screening. 
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Participants were randomized (1:1) to receive once-daily subcutaneous iGlarLixi 
(Suliqua®, [Soliqua®], Sanofi, Paris, France) or twice-daily subcutaneous BIAsp 30 (30% 
insulin aspart + 70% insulin aspart protamine; NovoMix® 30, Novo Nordisk A/S, Bagsværd, 
Denmark). iGlarLixi was injected before a meal using a prefilled disposable SoloSTAR® pen 
injector. BIAsp 30 was administered subcutaneously twice daily in the morning and before 
dinner. Participants were switched from their prior basal insulins at randomization; OADs 
were continued without adjustment. Starting doses of iGlarLixi were based on prior basal 
insulin doses, according to labelling instructions. If the previous basal insulin dose at 
randomization was <30 U, the starting dose was 20 dose steps (20 U iGlar, 10 μg Lixi) 
administered with the 10–40 U pen (2 U:1 μg ratio); if basal insulin was ≥30 to ≤50 U, the 
starting dose was 30 dose steps (30 U iGlar, 10 μg Lixi) administered with the 30–60 U pen 
(3 U:1 μg ratio). Further details are shown in Supplementary Table 1. Starting total daily 
doses of BIAsp 30 were the same as the participants’ previous basal insulin dose on a unit-to-
unit basis and split into two daily doses. Doses of iGlarLixi and BIAsp 30 were 
recommended for weekly titration based on fasting or premeal self-measured plasma glucose, 
respectively, to a target of 80–110 mg/dL (4.4–6.1 mmol/L). The recommended dose 
adjustment algorithms for iGlarLixi and BIAsp 30 were indicated according to label 
recommendations and are shown in Supplementary Tables 2 and 3. 
Rescue therapy use was recommended according to the investigator’s clinical judgment 
for both arms to correct hyperglycemia persisting beyond prespecified thresholds (HbA1c >8 
% or FPG >200 mg/dL from Week 12). Rescue therapy was to be considered in the iGlarLixi 
group when the maximal dose of 60 dose steps was reached. The use of any additional 
antihyperglycemic treatment (basal insulin, rapid-acting insulin, third daily injection of 
premix, or OADs) administered to participants in either group with the objective of rescue 
was included in the analysis of the proportion of participants requiring rescue therapy.  
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This study is registered on the European Union Drug Regulating Authorities Clinical 
Trials Database (2017-003370-13), and was conducted in accordance with the ethical 
principles of the Declaration of Helsinki, and the International Conference on Harmonisation 
guidelines for good clinical practice, and all applicable laws, rules, and regulations. 
Study endpoints 
The two primary objectives of this study were to demonstrate that, compared with BIAsp 
30, iGlarLixi was non-inferior in terms of HbA1c reduction or superior in terms of 
bodyweight change from baseline to Week 26. Key secondary efficacy endpoints were 
assessed at Week 26, including HbA1c <7 % without weight gain at Week 26, HbA1c <7 % 
without weight gain at Week 26 and without hypoglycemia (plasma glucose <70 mg/dL [<3.9 
mmol/L]) during the treatment period, and the superiority of iGlarLixi versus BIAsp 30 in 
terms of HbA1c reduction from baseline to Week 26. Other secondary exploratory glycemic 
endpoints included the proportion of patients reaching HbA1c target <7 % at Week 26, HbA1c 
target <7 % without ADA Level 2 hypoglycemia, HbA1c <7 % without weight gain of >1 kg, 
and HbA1c <6.5 %. Other secondary endpoints included change in total insulin dose and 
change in FPG, from baseline to Week 26.  
Safety endpoints were hypoglycemia, AEs, serious AEs (SAEs), AEs leading to treatment 
discontinuation, and AEs leading to death. Hypoglycemia was defined by current ADA Level 
1 (<70 mg/dL [<3.9 mmol/L] and ≥54 mg/dL [≥3.0 mmol/L]), Level 2 (<54 mg/dL [<3.0 
mmol/L]), or Level 3 (severe hypoglycemia). Nocturnal hypoglycemia was also assessed post 
hoc using two definitions: between bedtime and waking, and between 00:00–06:00 h. 
Statistical analysis 
 A sample size of 864 randomized participants (432 randomized or 388 evaluable 
participants per treatment group) was calculated based on the primary efficacy variables of 
HbA1c and weight change from baseline to Week 26. Assuming a drop-out rate of 10%, this 
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sample size provides over 95% power to demonstrate non-inferiority (margin 0.3 %) of 
iGlarLixi versus BIAsp 30 for HbA1c reduction or superiority for weight reduction at Week 
26. The assumptions made for non-inferiority of HbA1c were a standard deviation (SD) of 
1.1 %, a non-inferiority margin of 0.3 % and a zero true difference in HbA1c between 
treatment groups. Assumptions for superiority testing of iGlarLixi over BIAsp 30 in terms of 
weight gain included an expected difference of 1 kg between treatment groups and an SD of 
3.46 kg for changes from baseline. The two-sided significance level of 0.025 was assumed 
for each of the above tests.  
The primary efficacy endpoints were analyzed using a multiple imputation strategy 
and an ANCOVA model including screening HbA1c value (<8.0 % vs ≥8.0 %, for the change 
in bodyweight primary endpoint only), basal insulin dose (<30 U, ≥30 U) and SGLT2 
inhibitor use (Yes, No), treatment group, and country as fixed categorical effects, and fixed 
continuous covariates of baseline values for each primary endpoint (HbA1c and bodyweight).  
Continuous secondary efficacy endpoints (e.g. FPG and total daily insulin dose) were 
analyzed using the same approach as the primary endpoints including the baseline values for 
the endpoint in question as fixed covariates. Categorical secondary efficacy endpoints (e.g. 
the first two key secondary endpoints) were analyzed using a logistic regression model 
adjusting for treatment group randomization strata, and HbA1c and weight baseline 
covariates.  
A multiple testing procedure was pre-specified for analysis of the primary and key 
secondary efficacy endpoints (Supplementary Figure 1). Following the two primary 
endpoints, the three key secondary endpoints were assessed using a hierarchical order: 
superiority of iGlarLixi versus BIAsp 30 in achieving HbA1c <7 % without weight gain; then 
superiority of HbA1c <7 % without weight gain and without hypoglycemia; then superiority 
Premix RCT primary manuscript peer review  17 June 2021 
of HbA1c reduction. More detailed information pertaining to control for type I error has been 
previously published (22). 
All efficacy analyses were performed on data from the intention-to-treat (ITT) 
population, defined as all randomized participants. The COVID-19 pandemic occurred during 
the last few weeks of the study in some countries, making it difficult for some participants to 
comply with the protocol. To assess the potential impact of this on the primary and key 
secondary efficacy endpoints, sensitivity analyses were performed on a subgroup of the ITT 
population who had no major or critical deviations related to the COVID-19 pandemic 
situation that could have affected the primary efficacy analysis. Participants who followed the 
study visits and assessments without being impacted by the COVID-19 pandemic and its 
consequences (e.g. lockdown, sites closed, postponed/incomplete end-of-treatment visit) were 
defined as the non-impacted by COVID-19 population. Further sensitivity analyses were 
performed for the non-inferiority objective in the per protocol population, defined as all 
participants in the ITT population who completed 26 weeks of randomized treatment without 
any major protocol violations. 
Safety analyses were based on data from the safety population, defined as all 
randomized participants who received at least one dose of study drug.  
 
Results 
Participant disposition and baseline characteristics  
In total, 887 participants from 89 centers in 17 countries were randomized in the 
study, of whom 443 were allocated to iGlarLixi and 444 to BIAsp 30. Of the 887 participants 
in the ITT population, 403 in the iGlarLixi group and 404 in the BIAsp 30 group were 
included in the non-impacted by COVID-19 population. No participants discontinued due to 
COVID-19. Overall, participants received treatment with iGlarLixi or BIAsp 30 for a mean 
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duration of 184 or 181 days, respectively. In total, 844 (95.2%) participants completed the 
26-week treatment period; 428 (96.6%) in the iGlarLixi group and 416 (93.7%) in the BIAsp 
30 arm (Supplementary Figure 2). 
Demographics and baseline characteristics were similar across both treatment groups 
(Table 1) and have been reported previously (22). Briefly, the randomized population was 
primarily white (62.4%) with a mean ± SD age of 59.8 ± 10.2 years, BMI of 29.9 ± 4.9 kg/m2 
and duration of type 2 diabetes of 13.0 ± 7.2 years. Metformin was used at baseline in 99.8% 
of all participants: approximately one quarter were also receiving SGLT2i at baseline in both 
treatment groups. Basal insulins used at randomization were insulin glargine 100 U/mL 
(46%), insulin glargine 300 U/mL (22%), NPH insulin (21%), insulin detemir (7%), and 
insulin degludec (5%). 
 
Efficacy endpoints 
 The two primary efficacy endpoints and all three key secondary efficacy endpoints 
were met. Mean ± SD baseline HbA1c was 8.6 ± 0.7 % (71 ± 7 mmol/mol) in the iGlarLixi 
group and 8.6 ± 0.7 % (70 ± 7 mmol/mol) in the BIAsp 30 group. At Week 26, mean ± SD 
HbA1c had improved to 7.3 ± 1.1 % (56 ± 12 mmol/mol) in the iGlarLixi group and to 7.5 ± 
1.0 % (58 ± 11 mmol/mol) in the BIAsp 30 group (Figure 1A and 1B). Statistical non-
inferiority (margin 0.3 %) of iGlarLixi over BIAsp 30 was demonstrated for the change in 
HbA1c from baseline to Week 26 (LS mean difference [97.5% CI] vs BIAsp 30: -0.2 [-0.4, -
0.1] %; -2.6 [-4.5, -0.9] mmol/mol; p<0.001). Additionally, statistical superiority in HbA1c 
reduction from baseline to Week 26 of iGlarLixi over BIAsp 30 was demonstrated as part of 
the key secondary endpoint analysis, on the basis of the hierarchical testing procedure 
(Figure 1B). 
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At baseline, mean ± SD bodyweight was 80.7 ± 16.5 kg in the iGlarLixi group and 
82.2 ± 18.5 kg in the BIAsp 30 group. From baseline to Week 26, mean ± SD bodyweight 
decreased to 80.2 ± 16.6 kg for iGlarLixi and increased to 83.4 ± 19.0 kg for BIAsp 30 
(Figure 1C). Statistical superiority of iGlarLixi over BIAsp 30 was demonstrated for the 
change in bodyweight from baseline to Week 26 (LS mean difference vs BIAsp 30 -1.9 [95% 
CI -2.3, -1.4] kg; p<0.001).  
Key secondary efficacy endpoints showed that, compared with the BIAsp 30 group, a 
significantly greater proportion of participants in the iGlarLixi group reached HbA1c <7 % 
(<53 mmol/mol) without weight gain at Week 26, and without weight gain at Week 26 and 
without hypoglycemia (<70 mg/dL [<3.9 mmol/L]) during the treatment period (Figure 2). 
The percentage of participants who reached HbA1c target <7 % was higher in the iGlarLixi 
group than in the BIAsp 30 group (Figure 2, exploratory endpoint). iGlarLixi also 
demonstrated higher proportions of HbA1c <7 % target achievement without ADA Level 2 
hypoglycemia, HbA1c <7 % without weight gain of >1 kg, and HbA1c <6.5 % than BIAsp 30 
(Figure 2, exploratory endpoints). 
Mean ± SD FPG at baseline was 151 ± 44 mg/dL (8.4 ± 2.4 mmol/L) in the iGlarLixi 
group and 149 ± 41 mg/dL (8.3 ± 2.3 mmol/L) in the BIAsp 30 group. At Week 26, mean ± 
SD FPG was 130 ± 44 mg/dL (7.2 ± 2.4 mmol/L) in the iGlarLixi group and 146 ± 51 mg/dL 
(8.1 ± 2.8 mmol/L) in the BIAsp 30 group. The LS mean difference (95% CI) between 
groups in change from baseline to Week 26 was -16 (-26, -6) mg/dL (-0.9 [-1.5, -0.3] 
mmol/L). 
After 26 weeks, the increase in LS mean total daily insulin dose was smaller in the 
iGlarLixi group than in the BIAsp 30 (Figure 1D). The percentage of participants who 
required rescue therapy was low and similar for iGlarLixi (1.8%) and BIAsp 30 (2.3%). 
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 Detailed data for efficacy endpoints can be found in Supplementary Table 4. All key 
sensitivity analyses performed on the two primary and key secondary endpoints demonstrated 
similar results to those observed in the ITT population (Supplementary Table 5). 
 
Safety profile 
 The proportion of participants with at least one hypoglycemic event was lower in the 
iGlarLixi group compared with the BIAsp 30 group (OR [95% CI] 0.62 [0.47, 0.81]) (Figure 
3). Lower incidence of hypoglycemia with iGlarLixi versus BIAsp 30 was also observed 
across Level 1 and Level 2 hypoglycemia categories (Figure 3).  
Rates of hypoglycemia followed the same pattern as incidence. There was an overall 
lower rate of any hypoglycemia with iGlarLixi compared with BIAsp 30, as well as lower 
rates of Level 1 and Level 2 hypoglycemia (Figure 3). 
Three severe hypoglycemic episodes (Level 3) were reported: one occurred in the 
iGlarLixi group and two in the BIAsp 30 group. 
In addition, lower incidence (OR [95% CI]: 0.37 [0.16, 0.84]) and event rates (RR 
[95% CI]: 0.28 [0.11, 0.71]) of Level 2 nocturnal hypoglycemia (defined as occurring 
between bedtime and waking) were observed in the iGlarLixi group versus the BIAsp 30 
group. Similar patterns were seen when using the between 00:00–06:00 h definition: lower 
incidence (OR [95% CI]: 0.32 [0.12, 0.90]) and event rates (RR [95% CI]: 0.30 [0.10, 0.88]) 
were seen with iGlarLixi versus BIAsp 30. 
During the 26-week randomized treatment period, the percentage of participants who 
had at least one AE was slightly higher in the iGlarLixi group (32.6%) compared with the 
BIAsp 30 group (27.7%), the difference being mainly due to the higher incidence of GI 
events in the iGlarLixi group (10.4% vs 2.3%). A large proportion of these GI events were 
reported in the first week of treatment (Supplementary Figure 3). The most commonly 
Premix RCT primary manuscript peer review  17 June 2021 
reported AE in the iGlarLixi group was nausea (7.7% vs 0% for BIAsp 30), while 
nasopharyngitis was the most commonly reported AE in the BIAsp 30 group (2.7% vs 3.2% 
for iGlarLixi). In both treatment groups, the majority of participants had AEs considered mild 
or moderate in severity. SAEs were reported by a similar proportion of participants in both 
treatment groups (2.7% iGlarLixi and 2.9% BIAsp 30). Overall, the rate of study 
discontinuation due to an AE was low and similar in both treatment groups (0.9%). There 
were two fatal AEs (acute coronary syndrome and cardiac failure/pulmonary edema) during 
the study period, both in the BIAsp 30 group. Neither of these fatal AEs were considered 
related to study treatment. During the study, no AEs were considered related to COVID-19.  
Conclusions 
This study is the first RCT comparing an FRC of basal insulin and a GLP-1 RA with 
premix insulin. Results from this study provide evidence for the better efficacy and safety of 
iGlarLixi compared with premix BIAsp 30 for advancing treatment in adults with 
longstanding type 2 diabetes suboptimally controlled by basal insulin plus one or two OADs. 
After 26 weeks, iGlarLixi demonstrated both non-inferiority (primary endpoint) and 
statistical superiority (key secondary endpoint) to premix BIAsp 30 in HbA1c reduction and 
statistical superiority in bodyweight change (primary endpoint). Although the LS mean 
difference in HbA1c reduction was modest and may not represent a clinically meaningful 
difference in isolation, a greater proportion of participants achieved HbA1c target <7 % (<53 
mmol/mol) overall, as well as without weight gain or without weight gain and hypoglycemia 
with iGlarLixi versus BIAsp 30, demonstrating the overall clinical benefit of iGlarLixi in 
individuals with longstanding type 2 diabetes. 
In addition, mean bodyweight decreased from baseline to Week 26 with iGlarLixi and 
increased with premix BIAsp 30, with a significant between-group difference. Notably, better 
glucose control (HbA1c and FPG) observed with iGlarLixi compared with premix BIAsp 30 
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was associated with a smaller mean daily insulin dose at Week 26 in the iGlarLixi group 
compared with the premix BIAsp 30 arm. The between-treatment differences in Week 26 
FPG may also have contributed to the greater HbA1c reductions seen with iGlarLixi versus 
premix BIAsp 30; however, the lack of PPG data does limit our understanding of the cause of 
the between-treatment HbA1c change difference.  
These results align with a previous network meta-analysis (NMA) by Home et al. 
comparing iGlarLixi versus basal-bolus or premix insulins (24). Results of this NMA 
estimated greater HbA1c reductions with iGlarLixi versus premix insulin (mean difference of 
-0.50 [95% credible interval -0.93, -0.06] %), in addition to favorable bodyweight changes 
with iGlarLixi compared with premix insulin (-2.2 [-4.6, -0.1] kg) (24).  
The improvements in glycemic control and reductions in bodyweight seen with iGlarLixi 
in this study are consistent with those observed in the LixiLan-L study, which compared 
efficacy and safety of iGlarLixi versus basal insulin in people with longstanding type 2 
diabetes suboptimally controlled by basal insulin ± OAD therapy over 30 weeks (17). In 
LixiLan-L, LS mean reduction in HbA1c from baseline was 1.1 %, while weight was reduced 
by 0.7 kg. Similarly, the glycemic control and bodyweight changes observed for premix 
BIAsp 30 in the present study are consistent with previous RCTs of premix BIAsp 30 in 
adults with type 2 diabetes advancing basal insulin therapy (25-27).  
The incidence of hypoglycemia reported in previous RCTs of iGlarLixi and premix 
BIAsp 30 is difficult to compare with the current study due to the different definitions and 
blood glucose thresholds used (17; 26; 27). However, incidence of hypoglycemia in previous 
RCTs was generally higher for both treatments (40% for iGlarLixi and ~70% for premix 
BIAsp 30) than that observed in the present study (17; 26; 27), possibly due to the absence of 
sulfonylurea use in this study. It is, therefore, very encouraging that lower incidence and rates 
of hypoglycemia, including ADA Level 2 nocturnal hypoglycemia between bedtime and 
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waking, were still observed with iGlarLixi versus premix BIAsp 30 in the present study, 
despite iGlarLixi demonstrating better glycemic control.  
Likewise, the overall safety and tolerability profiles of iGlarLixi and premix BIAsp 30 
were comparable with those reported in previous studies (17-19; 26; 27), with very low 
discontinuation rates due to AEs and no unexpected safety signals identified. The slightly 
higher incidence of AEs observed for iGlarLixi versus premix BIAsp 30 in this study was due 
to the higher incidence of nausea in the iGlarLixi group. Nausea incidence in this study is in 
line with previous reports for FRCs (3.1%–10.4%) (17-22; 28), lower than previously 
observed in participants initiating GLP-1 RAs alone (18; 20), and very rarely led to treatment 
discontinuation (0.5%). Similarly, for both groups, low rates of SAEs were reported and few 
participants required rescue therapy (~2%). No AEs were determined to be COVID-19-
related.  
Following beta-cell decline in basal insulin-treated type 2 diabetes, prandial insulin is 
often added to control postprandial hyperglycemia (29; 30). An alternative option is adding a 
GLP-1 RA to basal insulin. Our results demonstrate that a co-formulation of basal insulin and 
GLP-1 RA (iGlarLixi) is more efficacious than a co-formulation of a basal insulin and a 
prandial insulin (premix BIAsp 30) when advancing therapy for people with type 2 diabetes 
suboptimally controlled on basal insulin alone. In addition to improving clinical outcomes, 
the lower incidence of hypoglycemia and the weight benefits observed with iGlarLixi may 
improve patient satisfaction, which could improve treatment adherence. Assessment of 
patient-reported outcomes from the current study is planned for future analyses. iGlarLixi 
may also prove to be a cost-effective alternative to premix with fewer injections and less 
glucose monitoring.  
A key strength of the present analysis is the evidence base generated by it being the 
first randomized head-to-head comparison of the efficacy and safety of an FRC of basal 
Premix RCT primary manuscript peer review  17 June 2021 
insulin and a GLP-1 RA versus premix insulin in a clinically relevant population of adults 
with type 2 diabetes who were suboptimally controlled on basal insulin plus OADs. 
Furthermore, it was a global study, including individuals with different ethnicities and from 
varying healthcare systems, without a glucose monitoring committee enforcing titrations and 
therefore provides relevant, clinically translatable information.  
 A potential limitation of this study is its open-label design. However, as the 
injectables could not be masked, a double-blind study design was impractical. Furthermore, 
iGlarLixi was tested against the most frequently used premix insulin ratio (30:70) but not 
against other premix ratios. However, hypoglycemia rates have been shown to be higher with 
other premix insulin regimens than with premix insulin 30/70 (31), so the benefits of 
iGlarLixi over other premix insulins could be even greater. A further potential limitation is 
that the COVID-19 pandemic occurred during the last few weeks of the study in some 
countries. Systems were put in place to ensure participant safety, retention and data capture. 
Sensitivity analyses in a non-impacted by COVID-19 ITT population showed that COVID-19 
was unlikely to have influenced the results of any endpoints assessed.  
 In conclusion, the once-daily FRC, iGlarLixi, is an efficacious and well-tolerated 
regimen that is simpler for the patient, providing better glycemic control with weight benefit 
and less hypoglycemia compared with premix BIAsp 30 as an alternative for advancing 
therapy in people with type 2 diabetes previously suboptimally controlled with basal insulin 
plus OADs.  
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Tables 
Table 1.  Abbreviated baseline characteristics (Randomized population) 
Demographic/clinical characteristic iGlarLixi BIAsp 30 All participants 
 (n=443) (n=444) (N=887) 
Age (years)    
Mean ± SD 59.8 ± 10.3 59.8 ± 10.0 59.8 ± 10.2 
Median 61 60 61 
(Q1, Q3) (52, 67) (54, 67) (53, 67) 
Sex, n (%)    
Male 224 (50.6) 218 (49.1) 442 (49.8) 
Female 219 (49.4) 226 (50.9) 445 (50.2) 
BMI (kg/m2)    
Mean ± SD 29.7 ± 4.7 30.0 ± 5.1 29.9 ± 4.9 
Median 29.1  29.2 29.1 
(Q1, Q3) (26.2, 32.9) (26.2, 34.2) (26.2, 33.6) 
Duration of type 2 diabetes (years)    
Mean ± SD 13.0 ± 7.1 13.0 ± 7.4 13.0 ± 7.2 
Median  12.0 12.0 12.0 
(Q1, Q3) (7.6, 17.0) (7.2, 17.0) (7.5, 17.0) 
Prior basal insulin at baseline*, n (%)    
Insulin glargine 100 U/mL 188 (42.4) 219 (49.2) 407 (45.8) 
Insulin glargine 300 U/mL 100 (22.6) 92 (20.7) 192 (21.6) 
NPH 102 (23.0) 82 (18.4) 184 (20.7) 
Insulin detemir 34 (7.7) 31 (7.0) 65 (7.3) 
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Insulin degludec 19 (4.3) 21 (4.7) 40 (4.5) 
Average basal insulin daily dose (U)†    
Mean ± SD 33.8 ± 9.6 33.8 ± 9.9 33.8 ± 9.8 
Median  34.0 34.0 34.0 
(Q1, Q3) (25.0, 40.0) (24.0, 42.0) (25.0, 40.0) 
Average basal insulin daily dose (U/kg)†    
Mean ± SD 0.43 ± 0.15 0.43 ± 0.14 0.43 ± 0.14 
Median  0.42 0.42 0.42 
(Q1, Q3) (0.32, 0.52) (0.32, 0.51) (0.32, 0.52) 
Previous non-insulin antihyperglycemic 
treatment*, n (%) 
  
 
Metformin 443 (100.0) 442 (99.5) 885 (99.8) 
SGLT2i 104 (23.5) 102 (23.0) 206 (23.2) 
Other 1 (0.2) 2 (0.5) 3 (0.3) 
Daily metformin dose at baseline (mg)    
Mean ± SD 1761 ± 542 1722 ± 549 1741 ± 546 
Median  2000 1850 2000 
(Q1, Q3) (1500, 2000) (1500, 2000) (1500, 2000) 
Diabetes-related complications, n (%)    
Diabetic neuropathy 119 (26.9) 127 (28.6) 246 (27.7) 
Diabetic retinopathy (incl. proliferative 
diabetic retinopathy) 
67 (15.1) 67 (15.1) 134 (15.1) 
Diabetic nephropathy 45 (10.2) 41 (9.2) 86 (9.7) 
Heart failure 11 (2.5) 8 (1.8) 19 (2.1) 
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Peripheral artery disease 2 (0.5) 9 (2.0) 11 (1.2) 
Ischemic stroke 2 (0.5) 0 2 (0.2) 
Full baseline characteristics have been reported previously (22). 
*A participant can be counted in more than 1 category. †Within the 3 days immediately 
before randomization. 
BIAsp 30, biphasic aspart insulin 30 (30% insulin aspart and 70% insulin aspart protamine); 
BMI, body mass index; iGlarLixi, a fixed-ratio combination of insulin glargine 100 U/mL 
and the glucagon-like peptide-1 receptor agonist, lixisenatide; NPH, neutral protamine 
Hagedorn insulin; OAD, oral antihyperglycemic drug; Q, quartile; SD, standard deviation; 
SGLT2i, sodium-glucose cotransporter 2 inhibitor. 
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Figure legends 
 Figure 1. (A) HbA1c over 26 weeks and (B) change in HbA1c, (C) bodyweight and (D) total 
insulin daily dose from baseline to Week 26 (ITT population) 
 
 
Missing data in the primary HbA1c and weight endpoints were imputed through a multiple 
imputation (MI) strategy under the missing not at random (MNAR) framework, with separate 
MI process function of treatment completeness. Missing values were imputed 1000 times. 
†Non-inferiority p value was calculated using a non-inferiority margin of 0.3 %. 
BIAsp 30, biphasic aspart insulin 30 (30% insulin aspart and 70% insulin aspart protamine); 
BL, baseline; CI, confidence interval; iGlarLixi, a fixed-ratio combination of insulin glargine 
100 U/mL and the glucagon-like peptide-1 receptor agonist, lixisenatide; ITT, intention-to-
treat; LS, least squares; SE, standard error, SD, standard deviation; W, week. 
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*Adjusted odds ratio of iGlarLixi versus BIAsp 30 with associated 2-sided CI (at the 
specified significance level that is passed from family 1 of the primary objectives), calculated 
by logistic regression model adjusted for fixed categorical effects of randomization strata 
(basal insulin dose at screening <30 U and ≥30 U; and SGLT2 inhibitor use [Yes, No] at 
screening) and treatment group as well as fixed continuous covariates of baseline values for 
each of the primary endpoints (HbA1c and bodyweight). 
†Imputed as not having reached HbA1c target (failure, ie. non-responder) in the case of 
missing HbA1c or weight values at Week 26. 
‡Weight gain defined as any increase >0 kg from baseline. 
§Hypoglycemia defined as plasma glucose <70 mg/dL (<3.9 mmol/L) occurring at any point 
within the 26-week open-label randomized treatment period. 
 
BIAsp 30, biphasic aspart insulin 30 (30% insulin aspart and 70% insulin aspart protamine); 
CI, confidence interval; iGlarLixi, a fixed-ratio combination of insulin glargine 100 U/mL 
and the glucagon-like peptide-1 receptor agonist, lixisenatide; ITT, intention-to-treat; n, 
number of participants; OR, odds ratio. 
Assessments were done in hierarchical order, starting with the proportion of participants who 
reached HbA1c <7 % without weight gain.
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Figure 3. (A) Incidence and (B) rates of hypoglycemic events over the 26-week treatment 
period (Safety population). 
 
*A participant can have more than one documented event.  
†Odds ratio for iGlarLixi versus BIAsp 30 and 95% CI based on logistic regression with 
treatment group (iGlarLixi and BIAsp 30) and randomization strata (HbA1c <8.0 % and ≥8.0 
%; basal insulin dose at screening <30 U and ≥30 U; and SGLT2 inhibitor use [Yes, No] at 
screening) as fixed effects. 
‡Rate ratio for iGlarLixi versus BIAsp 30 and 95% CI estimated from a negative binomial 
regression model with a log-link function, and the log of the time period in which a 
hypoglycemia episode is considered treatment emergent as offset. The model included fixed 
effect terms for treatment group (iGlarLixi and BIAsp 30) and randomization strata (HbA1c 
<8.0 % and ≥8.0 %; basal insulin dose at screening <30 U and ≥30 U; and SGLT2 inhibitor 
use [Yes, No] at screening). 
  
ADA, American Diabetes Association; BIAsp 30, biphasic aspart insulin 30 (30% insulin 
aspart and 70% insulin aspart protamine); CI, confidence interval; iGlarLixi, a fixed-ratio 
combination of insulin glargine 100 U/mL and the glucagon-like peptide-1 receptor agonist, 
lixisenatide; n, number of participants; OR, odds ratio; PPY, per participant-year; RR, rate 
ratio. 
 
 
 
